Results 61 to 70 of about 20,787 (190)

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2

Качественная клиническая практика, 2018
Usage of glucagon like peptide-1 receptors’ agonists (aGLP-1) is a new step in the treatment of Diabetes Mellitus Type 2 (DM 2). General attractive effects are positive effect on bodyweight, lower risk of hypoglycemia, compliance and possibility of ...
A. S. Kolbin, A. A. Mosikyan, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, W. Zhao   +5 more
doaj  

Special aspects of concentrated insulins: basic characteristics and research findings

Сахарный диабет, 2019
The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e.
Tatiana Y. Demidova, Olga V. Balutina
doaj   +1 more source

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes [PDF]

, 2018
AimsTo investigate the efficacy and safety of insulin glargine 300U/mL (Gla-300) vs insulin glargine 100U/mL (Gla-100) over 12months in a patient-level meta-analysis, using data from the EDITION studies in people with type 2 diabetes (T2DM).
American Diabetes Association, Becker, Bergenstal, Bolli, Donnelly, Home, Inzucchi, Matsuhisa, Nam, Oster, Peyrot, Polonsky, Riddle, Riddle, Ritzel, Steinstraesser, Terauchi, WHO, Yki-Järvinen, Yki-Järvinen, Yki-Järvinen   +20 more
core   +2 more sources

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen, Qiu Zhang, Binhong Duan, Xiaohong Wu, Hailong Wan, Binhong Wen, Jie Han, Haixia Liu, Caixian Yang, Weiwei Liu, Qin Du, Lei Kang, Minlu Zhang   +12 more
wiley   +1 more source

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives

Patient Preference and Adherence, 2016
Bastiaan E de Galan Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a ...
de Galan BE
doaj  

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA [PDF]

, 2017
Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please ...
Barnaby Hunt, Jakob Langer, Michelle Mocarski, William J. Valentine   +3 more
core   +2 more sources

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong, Yawen Zhang, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews [PDF]

, 2018
Background Successful treatments for gestational diabetes mellitus (GDM) have the potential to improve health outcomes for women with GDM and their babies. Objectives To provide a comprehensive synthesis of evidence from Cochrane systematic reviews of
Alsweiler, Jane, Brown, Julie, Crowther, Caroline A, Downie, Michelle R, Martis, Ruth, Shepherd, Emily   +5 more
core   +1 more source

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.

PLoS ONE, 2021
Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years.
Parag Goyal, Harish Venkatraman Pai, Phanichand Kodali, Bhavesh Vats, Navratna Vajpai, Shankara Annegowda, Krishnappa Mane, Shamini Mohan, Shruti Saxena, Anil Bangalore Veerabhadraia, Milee Palande, Preethy Sasankan Nair, Digvijay Chandrashekar More, Umamaheshwara Rao Karudumpa, Kunala Jyothirmai, Adroha Bhattacharya, Frida Almeida, Santosh Gulab Khyade, Shankara Gouda, Daniel J Ranayhossaini, Praveen Reddy Moole, Jeffrey P Smith, Abhijit Barve, Ramakrishnan Melarkode, Rajesh Ullanat   +24 more
doaj   +1 more source